111 (YI) EBITDA Margin (2017 - 2025)

111 (YI) posted EBITDA Margin of 0.01% for Q4 2025, up 85.02% sequentially from 0.08% in Q3 2025, and up 18.0% YoY from 0.01% in Q4 2024.

111 (YI) EBITDA Margin (2017 - 2025) Analysis & Trends

111 has reported EBITDA Margin for 9 years, with the latest figure at 0.01% in Q4 2025.

Quarterly EBITDA Margin rose 18.0% year-over-year to 0.01% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.02% (down 3.0% YoY) and the FY2025 annual result came in at 0.02%, down 3.0% from the prior year.
EBITDA Margin rose to 0.01% in Q4 2025 per YI's latest filing, from 0.08% in the prior quarter.
Over five years, EBITDA Margin peaked at 0.11% in Q1 2024 and troughed at 6.68% in Q1 2021.
A 5-year average of 2.06% and a median of 1.69% in 2023 frame the typical range for EBITDA Margin.
The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 241 bps in 2023, then surged 484 bps in 2024.
Over 5 years, EBITDA Margin stood at 3.03% in 2021, then climbed by 14 bps to 2.61% in 2022, then slumped by 92 bps to 5.03% in 2023, then jumped by 96 bps to 0.19% in 2024, then soared by 94 bps to 0.01% in 2025.
According to Business Quant data, EBITDA Margin over the past three periods registered 0.01%, 0.08%, and 0.0% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Mckesson	100.02 Bn	94.85 Bn	3.69 Bn	1.25%
2	Cencora	60.88 Bn	58.06 Bn	3.61 Bn	1.50%
3	Cardinal Health	54.14 Bn	49.29 Bn	2.56 Bn	1.14%
4	Henry Schein	10.05 Bn	9.90 Bn	1.10 Bn	4.95%
5	Akso Health	737.16 Mn	736.96 Mn	-	-
6	Edap Tms	159.12 Mn	137.58 Mn	7.34 Mn	-60.84%
7	Accendra Health	100.85 Mn	93.20 Mn	263.41 Mn	-5.73%
8	111	32.10 Mn	-26.65 Mn	18.18 Mn	-0.84%
9	Cosmos Health	12.73 Mn	10.29 Mn	1.51 Mn	-14.82%
10	VitaNova Life Sciences	11.51 Mn	9.91 Mn	264,662.00	-6.15%

Download Data